Navigation Links
Cynvenio Biosystems to Present Clinical Data on Mutational Analysis of LiquidBiopsy® Tumor Samples at the 2013 ASCO Annual Meeting
Date:5/28/2013

Westlake Village, CA (PRWEB) May 28, 2013

Cynvenio Biosystems, Inc., a cancer diagnostics company focused on the molecular analysis of tumor biomarkers derived from whole blood, today announced that clinical data from two research collaborations in breast and prostate cancer will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2013 taking place May 31-June 4, 2013 in Chicago. These data highlight the company’s progress in the molecular analysis of circulating tumor cells (CTC) by next generation sequencing.

The breast cancer study was completed with Fox Chase Cancer Center and the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia, Pennsylvania. The prostate cancer study was completed in collaboration with the Norris Comprehensive Cancer Center at the University of Southern California in Los Angeles.

Both studies demonstrate the feasibility of sequencing CTC populations isolated by LiquidBiopsy to discover disease-associated mutations. The potential of this approach is to monitor patients frequently over their entire cancer care cycle to determine the most appropriate treatment, measure response to therapy and, ultimately, screen the population for disease via a simple blood draw.

"These two studies further demonstrate the importance of applying new technology to the molecular analysis of cancer," said André de Fusco, president and CEO of Cynvenio Biosystems, Inc. "In oncology, as in all fields, better decisions are based on frequent analysis of the most up-to-date information - not less - and our goal is to place this capability within reach of every doctor and patient."

The schedule for poster presentations by Cynvenio Biosystems and its collaborators is:

Time and Date: 1:15-5:00 p.m. Saturday, June 1
Title: Classifying circulating mutation bearing tumor cells from breast cancer patients
Abstract Number: 115791
Poster Board Number: 6C
Session: General Poster Session: Breast Cancer
Type: Poster Session
Location: South Hall 2A
Presenters: William Strauss*, Paul W. Dempsey*, Jessamine Winer-Jones*, Catherine Bingham†, R. Katherine Alpaugh†, Massimo Cristofanilli‡; *Cynvenio Biosystems, Inc., Westlake Village, CA; †Fox Chase Cancer Center, Philadelphia, PA; ‡Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA.

Time and Date: 1:15-5:00 p.m. Monday, June 3
Title: Targeted Next Generation Sequencing (NGS) of Circulating Tumor Cells (CTCs) in Hormone-Sensitive Prostate Cancer
Abstract: 11040
Poster Board Number: 43C
Session: General Poster Session: Genitourinary Cancer, Prostate Cancer
Location: South Hall 2A
Presenters: Stephen Liu†, Paul Dempsey*, William Strauss*, Yucheng Xu†, Tong Xu†, Jacek Pinski†, Tanya Dorff†, David Quinn†, André de Fusco*, Tim Triche†, Janine McMurdie?, Amir Goldkorn†; *Cynvenio Biosystems, Inc., Westlake Village, CA; ?Life Technologies, Inc., Carlsbad, CA.; †University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.

About Cynvenio Biosystems, Inc.

Cynvenio Biosystems, Inc. is a molecular diagnostics company dedicated to the early detection and targeted treatment of cancer. Cynvenio has developed and deployed the LiquidBiopsy® system to enable realtime monitoring of tumor cell-associated mutations from a simple blood draw. This information can be used by physicians, academic centers, and drug developers to define treatment cycles for individual patients, efficiently select patients for drug trials and monitor patient response at any stage of disease.

Cynvenio’s CLIA service lab is based in Westlake Village, California. To find out more about the company please visit: http://www.cynvenio.com and http://www.liquidbiopsy.com.

LiquidBiopsy is a registered trademark of Cynvenio Biosystems, Inc.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10770579.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
2. Indigo Biosystems Among “Best Places to Work” in Indiana
3. Indigo Biosystems Nominated for Two TechPoint Mira Awards for Technology Excellence and Innovation
4. Genesis Biosystems Unveils Innovative Skin Treatment at Esthétique SPA International Trade Show
5. Lucas Bagnell Varga LLC Secures $17.4 Million Award For Former Applied Biosystems Executives
6. Aushon BioSystems and AH diagnostics unterzeichnen Distributionsvertrag für Skandinavien
7. Aushon BioSystems and AH diagnostics Sign Distribution Deal for Scandinavia
8. AyoxxA Biosystems Closes Series A Financing Round
9. Aushon BioSystems Appoints Martin Verhoef Chief Executive Officer
10. Ahram Biosystems Announces Launch of the New Economy Model F1-12 of Its Palm PCR Series
11. Lexicon To Present At The Deutsche Bank dbAccess Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology:
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
Breaking Biology News(10 mins):